Moyom Biotechnology Announces Strategic Partnership with WPP Group to Elevate Aphranel’s “Poetics of Time” Brand Positioning

Avatar photo

- Writer

Monday, 26 January 2026 - 14:48

facebook twitter whatsapp telegram line copy

URL berhasil dicopy

facebook icon twitter icon whatsapp icon telegram icon line icon copy

URL berhasil dicopy

SHANGHAI, Jan. 26, 2026 /PRNewswire/ — Moyom Biotechnology today announced a strategic partnership with WPP Group, a leading creative transformation company that provides integrated brand, media, public relations, data, and technology solutions worldwide.

Headquartered in London, WPP Group operates in more than 100 countries worldwide, integrating capabilities across creative, media, public relations, digital, consulting, and artificial intelligence. Through the partnership, WPP will draw on its global resources and integrated expertise to help Aphranel establish a clear, consistent, and internationally relevant, market-ready brand narrative, while communicating the values and the underlying scientific and clinical approach behind Poetics of Time to a broader professional audience.

Aphranel is a core brand of Moyom Biotechnology, positioned as the first CaHA-based regenerative injectable to receive regulatory approval in China. The brand is defined by an approach centered on a return to core medical principles, emphasizing structural support and long-term biological processes aligned with the natural rhythm of time.

"Poetics of Time" reflects Aphranel’s belief that aesthetic medicine should move beyond the notion of resisting aging, and instead focus on respecting anatomy, material science, and long-term clinical value. The partnership with WPP represents a key step in strengthening the brand’s global expression at the intersection of regenerative science and a clinically grounded, time-based medical philosophy.

Moyom Biotechnology said that it will continue working with WPP to expand the international reach of Aphranel and further build long-term brand trust and consistency across global markets.

Moyom Biotechnology Announces Strategic Partnership with WPP Group
Moyom Biotechnology Announces Strategic Partnership with WPP Group

About Aphranel

Aphranel is a core brand of Moyom Biotechnology, focused on professional medical aesthetics applications for clinical use. The brand specializes in facial injectables and regenerative materials, driven by science-based development and a sustained commitment to long-term clinical value.

About Moyom Biotechnology

Moyom Biotechnology is a medical technology company dedicated to regenerative materials and professional medical aesthetics, with a focus on science-based solutions and sustainable innovation in healthcare delivery.

About WPP

WPP is the creative transformation company. We use the power of creativity to build better futures for our people, planet, clients and communities. For more information, visit wpp.com.

Berita Terkait

Soprano Strengthens Global Security Credentials with Major Compliance Milestones
Horgos: A global hub where opportunity and belonging attract international entrepreneurs
KVB Futures Indonesia Launches Market Connect 2026 to Promote Safe and Responsible Trading Literacy
Waton Financial to Bring MoTA’s Multi-Agent Investment Platform to Individual Investors
DEEPX Expands APAC Footprint Through Distribution Agreement with Global Technology Distributor Avnet
OceanBase Recognized as a Strong Performer in Multimodel Data Platforms by Independent Research Firm
Trinasolar Powers 37MW RASLAG 4 Solar Project in the Philippines
This September, SIAL Guangzhou Unveils 7 Trends Shaping China’s F&B Industry

Berita Terkait

Monday, 13 July 2026 - 23:00

Soprano Strengthens Global Security Credentials with Major Compliance Milestones

Monday, 13 July 2026 - 14:42

Horgos: A global hub where opportunity and belonging attract international entrepreneurs

Monday, 13 July 2026 - 10:11

KVB Futures Indonesia Launches Market Connect 2026 to Promote Safe and Responsible Trading Literacy

Monday, 13 July 2026 - 10:00

Waton Financial to Bring MoTA’s Multi-Agent Investment Platform to Individual Investors

Monday, 13 July 2026 - 08:17

OceanBase Recognized as a Strong Performer in Multimodel Data Platforms by Independent Research Firm

Berita Terbaru